Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics (NASDAQ:TVRD)

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay Diagnostics

Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The company's

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

Crinetics (CRNX) Q1 2026 Earnings Transcript

This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.

This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.

This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.

Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology.

Crinetics (CRNX) Q4 2025 Earnings Call Transcript

As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused solely on the rare endocrine disorder Cushing’s syndrome, Corcept has evolved into a diversified clinical-stage powerhouse. While the company recently weathered a significant regulatory storm involving [...]

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

The company is preparing a rollout of its recently FDA-approved acromegaly treatment.

Crinetics Pharmaceuticals (CRNX) shows strong technical momentum and a high-quality consolidation setup, signaling a potential breakout opportunity for traders.